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Outcomes for patients with metastatic and recurrent Ewing sarcoma remain poor and a
better understanding of the biology of this malignancy is critical to the development of prog-
nostic biomarkers and novel therapies.Therefore, the Children’s Oncology Group (COG) has
created tissue banking protocols designed to collect high quality, clinically annotated, tumor
specimens that can be distributed to researchers to perform basic science and correlative
investigation. Data from the COG Ewing sarcoma tissue banking protocols AEWS02B1
and its successor study AEWS07B1 were reviewed in this study. Six-hundred and thirty
five patients were enrolled on AEWS02B1 and 396 patients have had tissue submitted to
AEWS07B1. The average age of participation was 13.2 years. About 86% were less than
19 years old and only 6% were greater than 21 years of age at diagnosis. When compared
to SEER data, approximately 18% of all cases and only 8% of all patients >20 years old
diagnosed with Ewing sarcoma annually in the United States have had tumor banked. The
majority of participants submitted formalin fixed, paraffin embedded, primary tumor and
blood samples. In total, fresh frozen tissue was submitted for only 29% of cases. Only
seven metastatic tumor samples have been collected. Although the COG has been suc-
cessful in collecting tumor samples from patients newly diagnosed with Ewing sarcoma,
fresh frozen tumor specimens from primary and metastatic disease are critically needed,
especially from young adult patients, in order to conduct high quality basic science and
translational research investigation with a goal of developing better treatments.
Keywords: Ewing sarcoma, tumor banking, biopsy, interventional radiology, bone tumor, adolescent and young
adult
INTRODUCTION
Ewing sarcoma is a solid tumor of bone and soft tissue that pri-
marily afflicts adolescents and young adults (Pizzo and Poplack,
2006; Karski et al., 2013). Ewing sarcoma can arise in any bone
of the body, although the most common sites of disease include
the pelvis, ribs, and long-bones of the extremities. Approximately
25% of patients have metastatic disease at diagnosis, most often
found in the lungs, bone, and bone marrow. The treatment of
Ewing sarcoma relies on a multidisciplinary approach, coupling
highly intensive chemotherapy with surgery, and/or radiotherapy
for control of the primary site of disease and metastatic lesions
(Arndt and Crist, 1999). Patients with overt metastases have a
<30% disease-free survival, while those with disease localized to
a single site generally have a >70% disease-free survival at 5 years
following diagnosis (Rodriguez-Galindo et al., 2003; Womer et al.,
2012). Furthermore, patients with metastatic disease have not
experienced improvements in outcomes in over 30 years (Grier
et al., 2003).
Ewing sarcomas are characterized genetically by the presence
of recurrent chromosomal translocations. In over 85% of cases
the translocation occurs between chromosomes 11 and 22 result-
ing in the creation of a pathognomonic chimeric fusion gene,
EWSR1/FLI1 that encodes the EWS/FLI protein (Delattre et al.,
1992). Alternative chromosomal translocations between mem-
bers of the EWSR1 and ETS gene families, such as t (21;22),
EWSR1/ERG, have been identified in the majority of cases that
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do not have a classic EWSR1/FLI1 fusion (Khoury, 2005). Since
its discovery 20 years ago, great insights into the biology of the
EWS/FLI protein in the initiation and progression of Ewing sar-
coma have been gained, but these discoveries remain to be trans-
lated into novel therapeutic strategies. A critical issue has been that
the EWS/FLI protein has not been effectively targeted by current
agents in the clinical setting. Thus, many investigators have sought
to better understand the underlying biology of Ewing sarcoma
with the goal of identifying new therapeutic strategies that might
be more efficacious and less toxic than current chemotherapeutic
approaches.
An important requirement for understanding the biology of
Ewing sarcoma is access to primary patient materials. Such mate-
rials include not only tumor tissue, but also specimens of bone
marrow, blood, serum, and genomic DNA (both tumor and germ
line). Shortly after the Children’s Oncology Group (COG) was
formed by the merger of four North American-centered pediatric
cancer groups [Pediatric Oncology Group (POG), Children’s Can-
cer Group (CCG), Intergroup Rhabdomyosarcoma Study Group
(IRSG), and National Wilms Tumor Study Group (NWTS)], a
commitment to obtaining and banking specimens from patients
with pediatric cancers was conceived. Collection of samples was
made on prior therapeutic studies, but these were protocol-specific
and not organized with a larger strategy in place.
The strategic Ewing sarcoma banking effort was initiated with
the development of COG protocol AEWS02B1, “A Groupwide
Biology and Banking Study for Ewing sarcoma,” which opened
on January 21, 2003, and closed on July 7, 2008. This study was
replaced by COG protocol AEWS07B1, “A Children’s Oncology
Group Protocol for Collecting and Banking Ewing Sarcoma Spec-
imens,” which opened for patient entry on February 4, 2008, and
remains open at the time of this report. The goal of these tumor
banking studies is to collect high quality tumor specimens with
associated demographic and clinical data that can be distributed
to researchers to perform basic science and correlative investiga-
tion that will improve the diagnosis, staging, risk-stratification,
and treatment of Ewing sarcoma.
As the COG-based Ewing sarcoma banking effort approaches
its tenth anniversary, we recognize the opportunity to review this
effort and to provide an overview of the resources that are available
to the research community. In this report we will highlight some
of the successes of these efforts, some challenges, and some issues
that have yet to be resolved. Finally, we provide information on
the process for sample requests and approval.
DESIGN AND AIMS OF THE COG EWING SARCOMA TUMOR
BANKING STUDIES
AEWS02B1
The goal of the AEWS02B1 tumor banking study was to develop
a mechanism to collect and distribute tumor specimens to inves-
tigators conducting basic science and translational research on
Ewing sarcoma. In addition, several important biologic aims were
incorporated into the study design, including determination of (1)
the prognostic significance of translocation subtype in Ewing sar-
coma; (2) the role of minimal residual disease (MRD) detection in
bone marrow specimens by RT-PCR determination of EWS/ETS
fusion genes; and (3) whether serum levels of IGF1 and IGFBP-3
are associated with clinical outcome. Additional exploratory aims
included analysis of gene expression profiles to identify novel mol-
ecular targets for treatment in Ewing sarcoma, establishment of
a bank of xenografts in SCID mice, and exploration of clinical
proteomics as a resource for investigations of altered signaling
molecules in the pathogenesis of Ewing sarcoma.
All participating centers had appropriate IRB approval and
informed consent was and/or assent was obtained prior to patient
enrollment. For each enrolled patient, institutions were required to
provide either a formalin fixed, paraffin embedded (FFPE) tissue
block or 10–20 FFPE unstained slides in addition to 1–3 thick
50µm sections. Whole blood and serum specimens were also
required. It was strongly recommended that additional specimens
be submitted including a bone marrow aspirate (2–4 ml in EDTA),
FFPE tissue blocks or slides obtained at the time of surgical resec-
tion and recurrence, and frozen primary tumor tissue frozen in
OCT media sent on dry ice.
AEWS07B1
The AEWS07B1 tumor banking study was designed to continue to
collect, bank, and store Ewing sarcoma tumor specimens. Unlike
AEWS02B1, there were no specific biologic aims included in the
study. Patients were required, at the time of diagnosis or recur-
rence, to submit a FFPE tissue block or 20 unstained FFPE slides,
whole blood and serum, and a pre-treatment bone marrow aspi-
rate (supplied as 2–4 ml in EDTA containing tubes). It was also
strongly recommended that additional frozen tumor samples pre-
served in either OCT media, RNA Later (Qiagen, Valencia, CA,
USA), or flash frozen in liquid nitrogen be submitted. For both
AEWS02B1 and AEWS07B1 protocols, each was approved by an
Institutional Review Board and informed consent was obtained
from all participants.
RESULTS
PATIENT DEMOGRAPHICS AND STUDY ACCRUAL
Between 2003 and 2008 a total of 635 patients from 85 insti-
tutions were enrolled on AEWS02B1. Thirteen patients were
declared ineligible either due to misdiagnosis, errors in the consent
process, or inadequate acquisition or shipment of tumor speci-
mens. AEWS07B1 was opened in 2008 and as of October 30, 2012,
470 patients were enrolled from 152 institutions. There has been
consistent and steady accrual on the tumor banking studies since
AEWS02B1 was opened on January 21, 2003. Fifty-six patients
were enrolled in 2003 and this low accrual was likely secondary to
institutional administrative delays in opening. Accrual was dou-
bled in 2004 (133 patients) and has remained relatively constant
with an average enrollment of 119 patients per year between 2004
and 2011 (Figure 1). There was a slight decrease in accrual from
2008–2010 likely attributed to the fact that there was not an open
therapeutic trial for localized Ewing sarcoma patients during this
time. The majority of patients enrolled on either banking study
were from the United States, as would be expected for a COG
study (brown bars, Figure 1).
Starting in 2007, COG opened the Cancer Control Registry
Network (CCRN), with a goal of registering all newly diagnosed
patients with cancer treated at COG institutions. To determine
what proportion of patients with Ewing sarcoma were being
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FIGURE 1 | Study accrual. Data as of March 21, 2012.
captured for AEWS07B1 up to age 21 (the CCRN age limit for
enrollment), we compared registration on the banking study
with the CCRN database. Since the collection of CCRN data,
approximately 80% of patients newly diagnosed with Ewing sar-
coma were also enrolled on AEWS07B1 (range 77–92%), rein-
forcing the hypothesis that younger patients (less than 21 years
old) treated at COG institutions are most likely to enroll on a
tissue banking study. Surveillance, Epidemiology, and End Result
(SEER) data from 2000–2009 estimates 574 new cases of bone and
soft tissue Ewing sarcoma each year in the United States and 321
cases under the age of 20 (SEER, 2011). These data suggest that
although accrual of patients who were diagnosed and treated at
COG affiliated institutions was high (80% of all patients enrolled
on the CCRN), only 18% (range 14–23%) of all predicted cases
of Ewing sarcoma and 28% (range 22–35%) of patients<20 years
old in the United States were enrolled on the banking studies.
Demographic data were collected for all enrolled patients and
are summarized in Table 1. The mean age for both studies was
approximately 13 years. As shown in Figure 2A, the majority of
patients were in their teenage years at diagnosis and relatively few
adult tumor samples were banked. Specifically, 86% of patients
that banked tumor specimens were less than 19 years old and only
6% were greater than 21 years old at the time of diagnosis. Per SEER
estimates, 44% of patients should be older than 20 years, with an
expected 191 patients diagnosed annually in the U.S. Thus, only
8% (range 6–10%) of patients >20 years were enrolled on these
studies.
To further illustrate the bias toward younger patients enrolled
on AEWS02B1 and AEWS07B1, the age of enrollment on the COG
biology protocols was compared to the predicted age estimate. In
this analysis, the number of patients at each age subset enrolled
on study was compared to the expected number at each age range
extrapolated from SEER estimates. For example, the SEER data
expects that 22% of all patients diagnosed with Ewing sarcoma
are between the ages of 15–19. Therefore, it would be expected
that 226 patients would have enrolled on the tumor banking
studies were 15–19 at diagnosis. In actuality, 328 patients ages
Table 1 | Patient Demographics1.
AEWS02B1 AEWS07B1 Total
Sex
Male 357 (56%) 237 (60%) 594
Female 278 (44%) 159 (40%) 437
Age (years)
0–4 54 34 88
5–9 108 69 177
10–14 204 123 327
15–19 197 131 328
20–24 52 32 84
25+ 20 7 27
1 As of March 21, 2012.
15–19 were enrolled on the study, or 32% of the total patient
population, suggesting that enrollment is biased toward younger
patients. Furthermore, when compared to SEER data from 2003
until 2009, 67% of patients diagnosed with EWS should be less
than 20 years old. However, as shown in Figure 2B, 89% of patients
were 19 years old or younger and significantly fewer patients over
25 years old were enrolled on study than what would be expected.
BANKED TISSUE SAMPLES
Table 2 lists the inventory of banked tumor specimens from both
AEWS02B1 and AEWS07B1. Serum and FFPE tissue were collected
from the majority of all participating patients (86 and 85%, respec-
tively). Bone marrow was submitted from 400 patients (38%), and
this percentage substantially increased after AEWS07B1 opened.
Fresh frozen (including OCT embedded) tissue was banked in
only 29% of patients (n= 304). Metastatic tumors were even more
rarely banked and, to date, tissue from metastatic sites has been
submitted for only seven patients (0.7%).
Table 2 and Figure 3 list the combinations of specimens sub-
mitted per patient. The most frequent combination submitted
by participating institutions was FFPE tissue (block or unstained
slides) and blood (N = 260, 28%), which were required on both
AEWS02B1 and AEWS07B1. Institutions that submitted only
stained hematoxylin and eosin stained slides were not counted,
resulting in 68 patients only submitting blood samples. The major-
ity of these patients (62 out of 68) were enrolled on AEWS02B1.
FFPE, blood, and bone marrow were submitted in 235 patients
(23%), but only 115 out of 1031 enrolled patients submitted
blood, bone marrow, FFPE, and fresh tissue (11%). About 29%
of enrollments included fresh frozen tumor tissue (Table 2).
CORRELATIVE STUDIES USING BANKED SPECIMENS AND PUBLISHED
MANUSCRIPTS
The purpose of the COG banking studies is to provide a resource of
high quality biologic materials that can be used for research inves-
tigation. Several defined COG group wide studies were included
within the aims of AEWS02B1 whereas AEWS07B1 was designed
to be more amenable to individual investigator-initiated research.
To evaluate the relative success of these banking studies we evalu-
ated the distribution of samples to investigators and the resulting
publications that included data from these studies. Although this
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FIGURE 2 | (A) Age of patient at time of sample submission. (B) Predicted enrollment per SEER estimates on 02B1 and 07B1 enrollment. Data as of March 21,
2012.
was not a systematic approach to identify all research projects that
have used Ewing sarcoma tissue bank samples, Table 3 lists a subset
of the published manuscripts that have used these samples. These
projects have contributed to both basic science discovery and
translational biology investigation in addition to providing special
collections of tissue samples necessary to answer critical biologic
questions. These banked tumor specimens have contributed to
the generation of novel scientific information that has resulted in
publication in high impact scientific journals (Table 3).
DISCUSSION
Since the Ewing sarcoma biology studies were opened and began
accruing patients in 2003, blood, tumor, and bone marrow spec-
imens have been banked from over 1000 patients with newly
diagnosed Ewing sarcoma. An estimated 18% of all cases of Ewing
sarcoma diagnosed in the United States were successfully banked
and as a result of these efforts, tumors and associated biologic
specimens have been distributed to investigators across North
America. The data generated by these studies have in turn gen-
erated basic science and translational insights that have advanced
our understanding of this malignant neoplasm. Tumor specimens
are banked at the Biopathology Center in Columbus, Ohio, and
are managed by the Ewing Sarcoma Bone Tumor Committee. The
Committee’s goal is to facilitate research focused on Ewing sar-
coma that will ultimately have an impact on the care of patients
with Ewing sarcoma. Thus, the Committee must balance a num-
ber of competing needs. On the one hand, the Committee strives
to ensure that all tumor bank specimens are being utilized in a
rigorous and scientific manner. On the other hand, the Commit-
tee tries to ensure that samples in the tumor bank are available to
investigators both now and in the future.
To ensure that these competing needs are met, the Ewing Sar-
coma Biology Committee has developed a sample request process
that starts with the submission of an investigator-initiated appli-
cation. The application is reviewed by three Committee members
as well as the Chair or Vice-Chair of the Committee. The Commit-
tee reviews applications for feasibility, use of resources, scientific
quality, and likely impact. A statistical review is also conducted to
ensure that studies are adequately powered to address the question
proposed. If the initial review is positive, the application is then dis-
cussed by the full Committee to ensure alignment of the study with
COG goals. Investigators are notified of the review outcome via
written response. This process ensures that all specimen requests
are reviewed in an objective and transparent manner to balance
the needs of the investigator with the mission of COG and the
Committee. This strategy has not only resulted in the generation
of many high quality publications, but has also ensured a large
inventory of tissue specimens for future studies.
However, despite these successes, the COG Ewing sarcoma biol-
ogy studies have had limitations. First, while there have been great
numbers of patients enrolled on the studies, the amount of tumor
specimens has lagged, especially with regards to snap-frozen spec-
imens. This has created some difficulties in gathering large num-
bers of high quality specimens required for some “genome-wide”
studies, such as RNA-based transcriptional profiling. One might
question why snap-frozen specimens are only “recommended”
rather than “required” for enrollment on Ewing sarcoma banking
studies. At issue is an attempt to balance ease of patient enroll-
ment (such that enrollment does not become restricted) with
the need for sample submission. It is clear that many institutions
only obtain limited amounts of primary tumor specimen at initial
biopsy. Once tumor material has been used for diagnostic pur-
poses, in many instances, very little remains for banking purposes.
At this time, there is no biomarker required for enrollment onto
a therapeutic study, and so it is unethical to require additional
tumor collection simply to satisfy the interest in expanding the
tumor bank. The Ewing Sarcoma Biology Committee is currently
studying a number of potential biomarkers that might find use in
therapeutic stratification of patients. If such a biomarker is iden-
tified, then it would become clinically relevant and appropriate
to require sample submission for enrollment onto a therapeutic
study.
A second challenge is that neither biology study provides cen-
tral review or independent molecular confirmation (i.e., FISH
or RT-PCR investigation of EWS fusions) of tumor specimens.
This information is available only if collected by the submitting
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Table 2 | Inventory of banked tumor specimens1.
Specimen AEWS02B1 AEWS07B1 Total
Formalin fixed paraffin embedded
primary tissue
524 345 869
Fresh tissue 182 122 304
FFPE metastatic tissue 1 1 2
Fresh metastatic tissue 4 1 5
Serum/plasma 551 336 887
Blood 310 343 653
Bone marrow, fresh 88 312 400
Bone marrow, FFPE 4 2 6
Urine 7 2 9
Type(s) of biological tissue submitted per patient
FFPE+blood 261 29 290
FFPE+blood+BM 54 181 235
FFPE+ fresh+blood 125 18 143
FFPE+ fresh+blood+BM 24 91 115
BLOOD only 62 6 68
FFPE only 44 15 59
None 24 9 33
Blood+BM 5 26 31
FFPE+ fresh 14 5 19
Fresh+blood 13 1 14
FFPE+BM 2 4 6
Fresh+blood+BM 2 4 6
FRESH only 4 1 5
BM only 1 4 5
FFPE+ fresh+BM 0 2 2
Fresh+BM 0 0 0
635 396 1031
1 As of March 21, 2012.
Formalin Fixed Paraffin Embedded (FFPE) primary tissue – includes unstained
slides, paraffin blocks, scroll.
Fresh tissue – includes OCT, snap frozen in liquid nitrogen, RNA later (Qiagen,
CA, USA).
Blood – includes Ficolled WBC, serum, and plasma, exclude unstained peripheral
blood slides.
Bone marrow, Fresh – includes Ficolled WBC or fresh frozen.
Bone marrow, FFPE – includes unstained slides.
Urine – includes frozen.
Not included – Normal tissue, Miscellaneous samples not otherwise specified.
institution. Centralized review of all tumor specimens might
not only increase accrual (by providing an additional “expert”
pathology second opinion for all enrolled patients),but would pro-
vide researchers additional confidence that all tumor specimens
have a confirmed pathologic diagnosis. This has become of greater
concern in recent years with the realization that there are a group
of “Ewing-like sarcomas” that phenocopy the bona fide disease,
but have alternate rare translocations (Sankar and Lessnick, 2011).
While these look-alike tumors are likely to constitute only a small
portion of enrolled patients, further study will be required to fully
understand the scope of this issue. At this time the COG Ewing
sarcoma biology Committee does not have the financial resources
required to perform central review of all submitted specimens.
FIGURE 3 | Distribution of tumor specimens.
A final challenge is that there is a serious need for tumor
specimens collected from patients greater than 20 years of age,
from metastatic sites, and from patients at relapse. Young adults
with Ewing sarcoma have a worse event free survival than younger
patients as do patients with metastatic disease at diagnosis (Cot-
terill et al., 2000; Yock et al., 2006; Leavey et al., 2008; Borinstein
et al., 2011). Whether there are specific biologic factors that lead
to this worse outcome is currently unknown. Investigation of this
age-based outcome discrepancy is warranted, but cannot be fully
addressed without a suitable collection of tumor specimens from
these cohorts of patients. Therefore, we strongly encourage sur-
geons, pathologists, medical oncologists, and pediatric oncologists
to work together to make tumor banking a priority. Adults are
often treated in hospitals that are not COG institutions. How-
ever, most academic medical centers are affiliated with pediatric
oncology programs that can assist in patient enrollment. These
interactions not only will result in increased participation of
older patients on Ewing sarcoma tumor banking studies, but will
foster cooperation between adult and pediatric providers and
will result in better care for our patients. Furthermore, the Sar-
coma Alliance for Research through Collaboration (SARC) has
recently been awarded a Specialized Program of Research Excel-
lence (SPORE) grant. One of the aims of this project is to collect
Ewing sarcoma tumor specimens from adult patients. Given the
close relationship between SARC and COG, we are optimistic that
this endeavor will result in the acquisition of more Ewing sar-
coma tumors from older individuals that can be used for scientific
discovery.
In light of these shortcomings, the COG Ewing sarcoma biology
committee proposes the following set of recommendations that
should result in improved accrual and availability of high quality
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Table 3 | Published manuscripts that have used tumor samples collected from AEWS02B1 and AEWS07B1.
Author (year) Title Journal
Douglas et al. (2008) BMI-1 promotes Ewing sarcoma tumorigenicity independent of CDKN2A repression Cancer Research
Joo et al. (2009) Gli1 is a central mediator of EWS/Fli1 signaling in Ewing tumors PLoS ONE
Bennani-Baiti et al. (2010) Intercohort gene expression co-analysis reveals chemokine receptors as prognostic indicators
in Ewing’s sarcoma
Clinical Cancer Research
Dubois et al. (2010) Flow cytometric detection of Ewing sarcoma cells in peripheral blood and bone marrow Pediatric Blood and Cancer
Jiang et al. (2010) CD133 expression in chemo-resistant Ewing sarcoma cells BMC Cancer
van Doorninck et al. (2010) Current treatment protocols have eliminated the prognostic advantage of type 1 fusions in
Ewing sarcoma: a report from the Children’s Oncology Group
Journal of Clinical Oncology
Borinstein et al. (2011) Investigation of the insulin-like growth factor-1 signaling pathway in localized Ewing sarcoma:
a report from the Children’s Oncology Group
Cancer
Cooper et al. (2011) Ewing tumors that do not overexpress BMI-1 are a distinct molecular subclass with variant
biology: a report from the Children’s Oncology Group
Clinical Cancer Research
Solomon et al. (2011) Mutational inactivation of STAG2 causes aneuploidy in human cancer Science
von Levetzow et al. (2011) Modeling initiation of Ewing sarcoma in human neural crest cells PLoS ONE
Jahromi et al. (2012) Molecular inversion probe analysis detects novel copy number alterations in Ewing sarcoma Cancer Genetics
FIGURE 4 | Optimal procurement of Ewing sarcoma tumor samples.
specimens and to produce a bank of tumors that will be suitable
for current molecular analytic techniques and also valuable for
future investigation.
BANKING OF FRESH TISSUE FROM PRE-TREATMENT SURGICAL
BIOPSY: RECOMMENDATIONS
Fresh viable tumor tissue represents an invaluable source of mate-
rial for clinically relevant studies in cancer biology. The ideal spec-
imen for obtaining such tissue is from a pre-treatment biopsy, a
sample obtained during the confirmation of relapse or metastases,
or surgical resection of a tumor. For some solid tumors, such as
Wilms tumors, which are resected prior to therapy, banking fresh
tissue is relatively feasible. However, for tumors such as Ewing sar-
coma, which are often only biopsied, from not easily accessible
sites, and then treated prior to resection, banking fresh tissue rep-
resents a greater challenge. Nonetheless, it is feasible in many cases,
and facilitated by a close working relationship between surgeon or
radiologist, pathologist and, if available, a local institutional COG
coordinator.
A possible protocol for fresh tissue banking is illustrated using
a real case in Figure 4. As for all tumor biopsies, the optimal
specimen is roughly a cubic centimeter of tumor tissue. After such
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tissue is obtained by the surgeon, a frozen section or touch prepa-
ration is performed by the pathologist. This is usually part of
the routine diagnostic protocol in order to verify viable tumor
tissue, provide an intraoperative differential diagnosis and guide
specimen allocation for optimal diagnostic work-up. Depending
on pathologist/institutional preference, if Ewing sarcoma is in the
differential diagnosis based on the frozen section or touch prepa-
ration, allocation might include any or all of the steps outlined
in Figure 4. All cases will include allocation of more viable tumor
tissue for permanent histology and immunohistochemical studies.
Depending on institutional practice, FFPE tissue can also be used
for FISH and RT-PCR molecular diagnostic studies, to support the
diagnosis of Ewing sarcoma or an alternative pathologic process.
If electron microscopic facilities are available, a small amount of
tissue may be preserved in glutaraldehyde for such studies. If facil-
ities for cytogenetic studies are available, fresh tissue may be sent
for cytogenetics and FISH. It is probably always prudent to freeze
at least a small amount of viable tumor tissue for other poten-
tial studies if needed, including molecular diagnostic studies on
fresh tissue. Additional fresh tissue may also be saved for possi-
ble flow cytometry, should subsequent pathologic examination of
FFPE tissue suggest a hematologic malignancy rather than Ewing
sarcoma. Once the above allocation has taken place, any remaining
tissue may be banked. In the real example illustrated in Figure 4,
approximately 30% of fresh biopsy tissue was banked without
compromising the clinical diagnosis.
With increasing incidence, especially for difficult-to-access
tumor sites, needle biopsy, conducted by either the surgeon or by
an interventional radiologist, is performed to acquire diagnostic
tumor tissue. Given the lack of tissue volume obtained using these
procedures, this poses significant impediment for tissue bank-
ing studies. However, these percutaneous biopsy procedures may
be optimized for the retrieval of adequate tissue and the avoid-
ance of complications which might alter the overall care of the
patient. In order to respect compartmental anatomy and plan for
the subsequent surgical approach with the necessity for resection
of the biopsy tract, image-guided biopsies are often performed
in consultation with surgical oncology input (Anderson et al.,
1999). Coaxial CT-guided biopsies, as shown in Figure 4, opti-
mize documentation of the needle path utilized, and allow for fine
needle aspiration (FNA) samples to be obtained prior to core nee-
dle biopsy of non-sclerotic osseous and soft tissue lesions. Given
the heterogeneity of some bone and soft tissue cancers, real-time
cytopathologist consultation of FNA samples assures that core
biopsies obtained from the same coaxial trajectory does repre-
sent viable lesional tissue rather than necrotic or non-diagnostic
material. In the event that the cytopathologist determines FNA
samples are inadequate, redirection prior to core biopsy is war-
ranted. Ultimately, in solid non-sclerotic soft tissue or bone lesions
the literature supports an average number of 5–6 core samples (16–
18 gage) be obtained for the purposes of diagnosis alone, and up
to 8–10 core biopsy samples in lesions demonstrating the greatest
degrees of heterogeneity. In medullary or cortical bone lesions with
varying degrees of sclerosis, hard bone biopsy devices, commonly
11-gage, or larger (Figure 5), provide sizeable specimens in fewer
passes (Jelinek et al., 2002; Puri et al., 2006). Communication with
FIGURE 5 | Interventional biopsy of a bone lesion: this figure depicts a
CT image of a vertebral bone biopsy using an 11-gage biopsy needle.
Optimum tumor acquisition is feasible with a smaller number of passes.
the surgeon or interventional radiologist performing these proce-
dures is crucial to assure that adequate tissue is obtained at the
time of biopsy and the pathologist should be present during the
procedure to assure adequacy of tissue.
It is recognized that the illustrated case represents a rather
ideal scenario that will not apply to all cases. Fresh tumor tis-
sue banking will be more challenging in cases where only smaller
biopsies are possible, or where the work-up indicates substan-
tial tumor necrosis or extensive intermixed normal tissue invaded
by tumor. In such cases, tissue needs for a confident diagnostic
work-up obviously supersede those for banking. However, it is
likely that at least small amounts of tissue can be banked from
many biopsies. We also strongly encourage physicians to submit
tissue from metastases when available after biopsy. Although often
metastatic sites are not biopsied at the time of diagnosis or relapse,
when performed, submission of this tissue for banking is opti-
mal. It cannot be overemphasized how critical such efforts are to
advancing our understanding of Ewing sarcoma pathobiology and
treatment.
SUMMARY AND CONCLUSIONS
Over the past 10 years, the COG has collected over 1000 Ewing
sarcoma primary tumor specimens that have been banked and
distributed to investigators. These tissue samples have been used
to advance our understanding of Ewing sarcoma pathogenesis. We
anticipate that the next decade will bring additional improvements
in treatment through a better understanding of the biology of this
devastating disease, especially for older patients with advanced
disease at presentation.
www.frontiersin.org March 2013 | Volume 3 | Article 57 | 7
Borinstein et al. Ewing sarcoma tumor banking experience
ACKNOWLEDGMENTS
We would like to thank all of the members of the COG Ewing sar-
coma biology committee for their input in the design and prepara-
tion of this manuscript. These research endeavors were supported
by the Chair’s Grant U10 CA98543 and Human Specimen Banking
Grant U24 CA114766 of the Children’s Oncology Group from the
National Cancer Institute, National Institutes of Health, Bethesda,
MD, USA. Additional support for research is provided by a grant
from the WWWW (QuadW) Foundation, Inc. (www.QuadW.org)
to the Children’s Oncology Group.
REFERENCES
Anderson, M. W., Temple, H. T., Dus-
sault, R. G., and Kaplan, P. A.
(1999). Compartmental anatomy:
relevance to staging and biopsy of
musculoskeletal tumors. AJR Am. J.
Roentgenol. 173, 1663–1671.
Arndt, C. A., and Crist, W. M. (1999).
Common musculoskeletal tumors
of childhood and adolescence. N.
Engl. J. Med. 341, 342–352.
Bennani-Baiti, I. M., Cooper, A., Lawlor,
E. R., Kauer, M., Ban, J., Aryee,
D. N., et al. (2010). Intercohort
gene expression co-analysis reveals
chemokine receptors as prognostic
indicators in Ewing’s sarcoma. Clin.
Cancer Res. 16, 3769–3778.
Borinstein, S. C., Barkauskas, D. A.,
Krailo, M., Scher, D., Scher, L.,
Schlottmann, S., et al. (2011). Inves-
tigation of the insulin-like growth
factor-1 signaling pathway in local-
ized Ewing sarcoma: a report from
the Children’s Oncology Group.
Cancer 117, 4966–4976.
Cooper, A., Van Doorninck, J., Ji, L.,
Russell, D., Ladanyi, M., Shimada,
H., et al. (2011). Ewing tumors that
do not overexpress BMI-1 are a dis-
tinct molecular subclass with variant
biology: a report from the Children’s
Oncology Group. Clin. Cancer Res.
17, 56–66.
Cotterill, S. J., Ahrens, S., Paulussen, M.,
Jurgens, H. F., Voute, P. A., Gadner,
H., et al. (2000). Prognostic factors
in Ewing’s tumor of bone: analysis
of 975 patients from the European
Intergroup Cooperative Ewing’s Sar-
coma Study Group. J. Clin. Oncol. 18,
3108–3114.
Delattre, O., Zucman, J., Plougastel,
B., Desmaze, C., Melot, T., Peter,
M., et al. (1992). Gene fusion
with an ETS DNA-binding domain
caused by chromosome transloca-
tion in human tumours. Nature 359,
162–165.
Douglas, D., Hsu, J. H., Hung, L.,
Cooper, A., Abdueva, D., Van
Doorninck, J., et al. (2008).
BMI-1 promotes Ewing sarcoma
tumorigenicity independent of
CDKN2A repression. Cancer Res.
68, 6507–6515.
Dubois, S. G., Epling, C. L., Teague,
J., Matthay, K. K., and Sinclair, E.
(2010). Flow cytometric detection
of Ewing sarcoma cells in periph-
eral blood and bone marrow. Pediatr.
Blood Cancer 54, 13–18.
Grier, H. E., Krailo, M. D., Tarbell, N.
J., Link, M. P., Fryer, C. J., Pritchard,
D. J., et al. (2003). Addition of
ifosfamide and etoposide to stan-
dard chemotherapy for Ewing’s sar-
coma and primitive neuroectoder-
mal tumor of bone. N. Engl. J. Med.
348, 694–701.
Jahromi, M. S., Putnam, A. R., Druz-
gal, C., Wright, J., Spraker-Perlman,
H., Kinsey, M., et al. (2012). Molec-
ular inversion probe analysis detects
novel copy number alterations in
Ewing sarcoma. Cancer Genet. 205,
391–404.
Jelinek, J. S., Murphey, M. D., Welker, J.
A., Henshaw, R. M., Kransdorf, M. J.,
Shmookler, B. M., et al. (2002). Diag-
nosis of primary bone tumors with
image-guided percutaneous biopsy:
experience with 110 tumors. Radiol-
ogy 223, 731–737.
Jiang, X., Gwye, Y., Russell, D., Cao,
C., Douglas, D., Hung, L., et al.
(2010). CD133 expression in chemo-
resistant Ewing sarcoma cells. BMC
Cancer 10:116. doi:10.1186/1471-
2407-10-116
Joo, J., Christensen, L., Warner, K.,
States, L., Kang, H. G., Vo, K.,
et al. (2009). GLI1 is a cen-
tral mediator of EWS/FLI1 signal-
ing in Ewing tumors. PLoS ONE
4:e7608. doi:10.1371/journal.pone.
0007608
Karski, E. E., Matthay, K. K., Neuhaus,
J. M., Goldsby, R. E., and Dubois, S.
G. (2013). Characteristics and out-
comes of patients with Ewing sar-
coma over 40 years of age at diag-
nosis. Cancer Epidemiol. 37, 29–33.
Khoury, J. D. (2005). Ewing sarcoma
family of tumors. Adv. Anat. Pathol.
12, 212–220.
Leavey, P. J., Mascarenhas, L., Marina,
N., Chen, Z., Krailo, M., Miser, J.,
et al. (2008). Prognostic factors for
patients with Ewing sarcoma (EWS)
at first recurrence following multi-
modality therapy: a report from the
Children’s Oncology Group. Pediatr
Blood Cancer 51, 334–338.
Pizzo, P. A., and Poplack, D. G. (2006).
Principles and Practice of Pediatric
Oncology. Philadelphia: Lippincott
Williams & Wilkins.
Puri, A., Shingade,V. U., Agarwal, M. G.,
Anchan, C., Juvekar, S., Desai, S., et
al. (2006). CT-guided percutaneous
core needle biopsy in deep seated
musculoskeletal lesions: a prospec-
tive study of 128 cases. Skeletal
Radiol. 35, 138–143.
Rodriguez-Galindo, C., Spunt, S. L.,
and Pappo, A. S. (2003). Treat-
ment of Ewing sarcoma family of
tumors: current status and outlook
for the future. Med. Pediatr. Oncol.
40, 276–287.
Sankar, S., and Lessnick, S. L. (2011).
Promiscuous partnerships in
Ewing’s sarcoma. Cancer Genet. 204,
351–365.
SEER. (2011). Surveillance, Epidemiol-
ogy, and End Results (SEER) Program
Populations (1969–2009). Available
at: www.seer.cancer.gov
Solomon, D. A., Kim, T., Diaz-Martinez,
L. A., Fair, J., Elkahloun, A. G., Har-
ris, B. T., et al. (2011). Mutational
inactivation of STAG2 causes aneu-
ploidy in human cancer. Science 333,
1039–1043.
van Doorninck, J. A., Ji, L., Schaub,
B., Shimada, H., Wing, M. R.,
Krailo, M. D., et al. (2010). Cur-
rent treatment protocols have elim-
inated the prognostic advantage of
type 1 fusions in Ewing sarcoma: a
report from the Children’s Oncol-
ogy Group. J. Clin. Oncol. 28,
1989–1994.
von Levetzow, C., Jiang, X., Gwye,
Y., Von Levetzow, G., Hung, L.,
Cooper, A., et al. (2011). Model-
ing initiation of Ewing sarcoma in
human neural crest cells. PLoS ONE
6:e19305. doi:10.1371/journal.pone.
0019305
Womer, R. B., West, D. C., Krailo, M.
D., Dickman, P. S., Pawel, B. R.,
Grier, H. E., et al. (2012). Ran-
domized controlled trial of interval-
compressed chemotherapy for the
treatment of localized Ewing Sar-
coma: a report from the Children’s
Oncology Group. J. Clin. Oncol. 30,
4148–4154.
Yock, T. I., Krailo, M., Fryer, C. J., Don-
aldson, S. S., Miser, J. S., Chen, Z.,
et al. (2006). Local control in pelvic
Ewing sarcoma: analysis from INT-
0091 – a report from the Children’s
Oncology Group. J. Clin. Oncol. 24,
3838–3843.
Conflict of Interest Statement: The
authors declare that the research was
conducted in the absence of any com-
mercial or financial relationships that
could be construed as a potential con-
flict of interest.
Received: 18 January 2013; paper pending
published: 10 February 2013; accepted: 03
March 2013; published online: 20 March
2013.
Citation: Borinstein SC, Beeler N, Block
JJ, Gorlick R, Grohar P, Jedlicka P, Krailo
M, Morris C, Phillips S, Siegal GP, Lawlor
ER, Lessnick SL and COG Ewing Sarcoma
Biology Committee (2013) A decade in
banking Ewing sarcoma: a report from the
Children’s Oncology Group. Front.Oncol.
3:57. doi:10.3389/fonc.2013.00057
This article was submitted to Frontiers in
Pediatric Oncology, a specialty of Fron-
tiers in Oncology.
Copyright © 2013 Borinstein, Beeler,
Block, Gorlick, Grohar, Jedlicka, Krailo,
Morris, Phillips, Siegal, Lawlor, Lessnick
and COG Ewing Sarcoma Biology Com-
mittee. This is an open-access article dis-
tributed under the terms of the Creative
Commons Attribution License, which
permits use, distribution and reproduc-
tion in other forums, provided the original
authors and source are credited and sub-
ject to any copyright notices concerning
any third-party graphics etc.
Frontiers in Oncology | Pediatric Oncology March 2013 | Volume 3 | Article 57 | 8
